000127445 001__ 127445
000127445 005__ 20240228140928.0
000127445 0247_ $$2doi$$a10.1016/j.tiv.2014.12.019
000127445 0247_ $$2pmid$$apmid:25572481
000127445 0247_ $$2ISSN$$a0887-2333
000127445 0247_ $$2ISSN$$a1879-3177
000127445 037__ $$aDKFZ-2017-03468
000127445 041__ $$aeng
000127445 082__ $$a610
000127445 1001_ $$aSavary, Camille C$$b0
000127445 245__ $$aTranscriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period.
000127445 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2015
000127445 3367_ $$2DRIVER$$aarticle
000127445 3367_ $$2DataCite$$aOutput Types/Journal article
000127445 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521711922_2108
000127445 3367_ $$2BibTeX$$aARTICLE
000127445 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127445 3367_ $$00$$2EndNote$$aJournal Article
000127445 520__ $$aPrevious works have shown that differentiated human HepaRG cells can exhibit drug metabolism activities close to those of primary human hepatocytes for several weeks at confluence. The present study was designed to evaluate their long-term functional stability and their response to repeated daily drug treatments over a 14-day period, using a transcriptomic approach. Our data show that less than 1% of the expressed genes were markedly deregulated over this two weeks period and mainly included down-regulation of genes related to the cell cycle and from 3 days, overexpression of genes involved in xenobiotic and lipid metabolism. After daily treatment with the three PPAR agonists, fenofibrate, troglitazone and rosiglitazone qualitative and/or quantitative changes in gene profiling were observed depending on the compound and duration of treatment. The highest increase in the number of deregulated genes as a function of drug treatment was seen with rosiglitazone. The most up-regulated genes common across the three compounds were mainly related to lipid and xenobiotic metabolisms. All the data support the conclusion that human HepaRG cells have an exceptional functional stability at confluence and that they are suitable for investigations on chronic effects of drugs and other chemicals.
000127445 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000127445 588__ $$aDataset connected to CrossRef, PubMed,
000127445 650_7 $$2NLM Chemicals$$aChromans
000127445 650_7 $$2NLM Chemicals$$aHypoglycemic Agents
000127445 650_7 $$2NLM Chemicals$$aHypolipidemic Agents
000127445 650_7 $$2NLM Chemicals$$aPeroxisome Proliferator-Activated Receptors
000127445 650_7 $$2NLM Chemicals$$aThiazolidinediones
000127445 650_7 $$005V02F2KDG$$2NLM Chemicals$$arosiglitazone
000127445 650_7 $$0I66ZZ0ZN0E$$2NLM Chemicals$$atroglitazone
000127445 650_7 $$0U202363UOS$$2NLM Chemicals$$aFenofibrate
000127445 7001_ $$0P:(DE-He78)079436c5442874052d541943e53145ef$$aJiang, Xiaoqi$$b1$$udkfz
000127445 7001_ $$aAubry, Marc$$b2
000127445 7001_ $$aJossé, Rozenn$$b3
000127445 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b4$$udkfz
000127445 7001_ $$aHewitt, Philip$$b5
000127445 7001_ $$aGuillouzo, André$$b6
000127445 773__ $$0PERI:(DE-600)1501079-x$$a10.1016/j.tiv.2014.12.019$$gVol. 30, no. 1 Pt A, p. 27 - 35$$n1 Pt A$$p27 - 35$$tToxicology in vitro$$v30$$x0887-2333$$y2015
000127445 909CO $$ooai:inrepo02.dkfz.de:127445$$pVDB
000127445 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)079436c5442874052d541943e53145ef$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000127445 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000127445 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000127445 9141_ $$y2015
000127445 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000127445 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127445 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127445 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTOXICOL IN VITRO : 2015
000127445 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127445 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000127445 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000127445 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127445 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127445 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127445 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127445 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000127445 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127445 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000127445 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000127445 980__ $$ajournal
000127445 980__ $$aVDB
000127445 980__ $$aI:(DE-He78)C060-20160331
000127445 980__ $$aUNRESTRICTED